Skip to content
Citation only via Europe PMC

Plasma-derived hyperhomocysteinemia, PGAM5, and oligomeric α-synuclein as a biomarker panel for idiopathic Parkinson's disease.

Feng F, Du Y, Xu B, Hou J, Su Y, Jiang T, Chen K, Qian J, Xie C, Chen H.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026

Abstract

<h4>Objective</h4>This study aimed to assess a novel panel of plasma biomarkers, comprising homocysteine (HCY), phosphoglycerate mutase 5 (PGAM5), and oligomeric α-synuclein, for the diagnosis of Parkinson's disease (PD) and to investigate the mechanistic interactions among these biomarkers.<h4>Methods</h4>In this cross-sectional study, serum HCY was measured in all 150 patients with PD and 113 healthy controls (HCs), whereas plasma PGAM5 and oligomeric α-synuclein were assayed in subsets (80 PD/78 HC and 67 PD/89 HC, respectively). The diagnostic associated risk factors, and interrelationships of these biomarkers were analyzed using receiver operating characteristic (ROC) curve analysis, multivariable logistic regression, and mediation analysis, respectively. Additionally, a diagnostic nomogram was constructed.<h4>Results</h4>Plasma levels of HCY, PGAM5, and oligomeric α-synuclein were significantly elevated in individuals with PD (all P < 0.001). The combined biomarker panel yielded an area under the curve (AUC) of 0.89 for PD diagnosis, which increased to 0.93 when integrated with the rapid eye movement sleep behavior disorder (RBD) questionnaire score. HCY was an independent risk factor for PD and was associated with male sex, older age, hypertension, longer disease duration, and more severe motor/cognitive deficits (all P < 0.01). Oligomeric α-synuclein mediated 25.72% of the association between HCY and PD (P < 0.001).<h4>Conclusions</h4>This study validates a high-performance plasma biomarker panel for PD, identifies HCY as a risk factor for severe disease progression, and provides clinical evidence that oligomeric α-synuclein mediates the neurotoxic effect of HCY, highlighting a promising therapeutic target.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
Europe PMC
DOI
10.1007/s10072-026-09533-z
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
F, F., Y, D., B, X., J, H., Y, S., T, J., K, C., J, Q., C, X., &amp; H., C. (2026). Plasma-derived hyperhomocysteinemia, PGAM5, and oligomeric α-synuclein as a biomarker panel for idiopathic Parkinson's disease. <em>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</em>. https://doi.org/10.1007/s10072-026-09533-z
Vancouver
F F, Y D, B X, J H, Y S, T J, et al. Plasma-derived hyperhomocysteinemia, PGAM5, and oligomeric α-synuclein as a biomarker panel for idiopathic Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2026. doi:10.1007/s10072-026-09533-z.
BibTeX
@article{feng2026Plasma, title = {Plasma-derived hyperhomocysteinemia, PGAM5, and oligomeric α-synuclein as a biomarker panel for idiopathic Parkinson's disease.}, author = {Feng F and Du Y and Xu B and Hou J and Su Y and Jiang T and Chen K and Qian J and Xie C and Chen H.}, journal = {Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology}, year = {2026}, doi = {10.1007/s10072-026-09533-z}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings